Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for ...
Scholar Rock (SRRK) announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial will be presented in multiple clinical ...
Dark matter could be an entire dark sector of the universe, with its own particles and forces H ave you ever stood by the sea ...
“A new era in genetic testing has arrived,” said Carlos Bustamante, Ph.D., CEO & Co-Founder, Galatea Bio. “StrataRisk PRS empowers clinical genetic labs to deliver more informative reports to ...
The EU's retaliatory tariffs will now take effect in mid-April to allow time for talks with the U.S., officials said.
Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...
Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ETCompany ParticipantsCarlo Broos - Interim Chief Financial ...
Fast Company on MSN1dOpinion
Why the climate tech industry needs outsidersThe idea that climate tech needs deep environmental knowledge is a misconception. What’s truly needed are professionals who ...
Space on MSN1d
Euclid space telescope's 1st results reveal 'a goldmine of data' in search for dark matter and dark energy (images, video)The Euclid space telescope has dropped its first data and deep field observations showing millions of galaxies in great ...
Anthony Bergmann; Chief Financial Officer; Capricor Therapeutics Inc. Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc. Edward T ...
News-Medical.Net on MSN2d
In the Thymus We Trust: ProTcell Therapy & the Future of Allogeneic ImmunotherapyIn this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy is being revolutionized.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback